Addex Therapeutics (ADXN) Company Report

Addex Therapeutics concluded Q3 2025 with CHF 2.2 million in cash, providing a cash runway through mid-2026; however, current cash does not fund the progression of unpartnered programs into the clinic.
The company advanced its GABA-B PAM program for chronic cough, with IND-enabling studies ready to commence subject to securing financing. Separately, partner Indivior successfully completed IND-enabling studies for their GABA-B PAM candidate for substance use disorders, making Addex eligible for up to $330 million in milestones and tiered royalties.
Dipraglurant, an mGluR5 negative allosteric modulator, has been repositioned for brain injury recovery, with good progress made in preparing the program for clinical studies.
Addex's spin-out company, Neurosterix, is advancing its M4 PAM program, which is on track to dose patients this year. Additionally, Addex highlighted progress by Stalicla, a company it invested in, which is advancing its patient stratification study in autism and working on Series C financing.

3 days ago

ADX Therapeutics Reports Q3 2025 Financial Results and Pipeline Updates

ADXN

Earnings

Guidance Update

New Projects/Investments

ADX Therapeutics concluded Q3 2025 with CHF 2.2 million in cash, projecting a cash runway through mid-2026, though this does not cover the progression of unpartnered programs into clinical stages.
For Q3 2025, the company recorded $100,000 in income, $200,000 in R&D expenses, and $500,000 in G&A expenses, alongside a $900,000 share of net loss from its Neurosterix investment.
The GABA B PAM program for chronic cough is ready to commence IND enabling studies, contingent on securing financing, following successful preclinical characterization.
Partner Indivior has completed IND enabling studies for their GABA B PAM drug candidate, which could lead to up to $330 million in milestone payments and tiered royalties for ADX.
ADX's spinout, Neurosterix, completed IND enabling studies for its M4 PAM program, with plans to dose patients this year.

3 days ago

Addex Therapeutics Reports Q3 2025 Financials and Pipeline Progress

ADXN

Earnings

New Projects/Investments

Guidance Update

Addex Therapeutics reported CHF 0.1 million in income, CHF 0.2 million in R&D expenses, and CHF 0.5 million in G&A expenses for Q3 2025.
The company completed Q3 2025 with CHF 2.2 million in cash, providing a cash runway through mid-2026, though this cash is insufficient to fund the progression of unpartnered programs into the clinic.
Significant progress was made in the GABA-B PAM program for chronic cough, with IND-enabling studies ready to start subject to securing financing.
Partner Indivior successfully completed IND-enabling studies for their GABA-B PAM program, making Addex eligible for payments up to $330 million and tiered royalties. The Dipraglurant Post-Stroke Recovery Program is also being prepared for clinical studies.

3 days ago

Addex Therapeutics Reports Q3 2025 Financial Results and Corporate Update

ADXN

Earnings

Guidance Update

New Projects/Investments

Addex Therapeutics reported a net loss of CHF 1,577 thousand for the third quarter of 2025 and a net loss of CHF 4,891 thousand for the nine-month period ended September 30, 2025.
As of September 30, 2025, the company held CHF 2,187 thousand in cash and cash equivalents, which is expected to fund operating expenses and capital expenditure requirements through mid-June 2026.
The company is advancing its GABAB PAM chronic cough candidate through preclinical development and preparing dipraglurant for clinical studies in post-stroke recovery.
Addex is eligible for up to USD 330 million in success-based development and regulatory milestones, plus tiered royalties, from its agreement with Indivior, which recently selected a compound for development in substance use disorders.
The license agreement with Janssen Pharmaceuticals Inc. was terminated on April 17, 2025, and the mGlu2 PAM program, including all related intellectual property, was returned to Addex after a Phase 2a clinical trial did not achieve statistical significance for its primary endpoint.

3 days ago

Addex Therapeutics Reports H1 2025 Financials and Pipeline Progress

ADXN

Earnings

New Projects/Investments

Addex Therapeutics completed H1 2025 with CHF 2.3 million in cash, providing a cash runway through mid-2026, though current cash does not fund the progression of unpartnered programs into the clinic.
The company's partner, Indivior, successfully completed IND enabling studies for a GABA B PAM drug candidate for substance use disorders, making Addex eligible for up to $330 million in milestones and tiered royalties.
Addex is advancing its independent GABA B PAM program for chronic cough, having substantially completed preclinical profiling with robust anti-tussive data, and is ready to start IND enabling studies subject to securing financing.
Neuroserx, in which Addex holds a 20% equity interest, has made excellent progress, completing IND enabling studies for its m4 PAM program and is on track to dose patients this year.